<DOC>
	<DOCNO>NCT01221727</DOCNO>
	<brief_summary>This multi-center , open-label , drug-drug interaction study postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>The Effects Denosumab Pharmacokinetics ( PK ) Midazolam</brief_title>
	<detailed_description>Approximately 27 subject ( Group A : 18 ; Group B : 9 ) receive 2 mg oral dose midazolam day 1 follow 24 hour PK collection . Subjects randomize Group A receive single 60 mg subcutaneous ( SC ) dose denosumab day 2 administer abdomen . On study day 16 , another 2 mg oral dose midazolam administer subject ( Groups A B ) follow 24 hour PK collection . The primary analysis determine effect denosumab PK midazolam base data subject Group A .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Between 45 75 year age Postmenopausal woman Osteoporosis Use know inhibitor cytochrome P450 3A4/Pgp ( CYP3A4 ) within 14 day 5 half life , whichever longer ; grapefruit juice grapefruit containing product within 7 day prior investigational product administration Use know CYP3A4 inducer within 30 day 5 halflives , whichever longer , prior investigational product administration Use herbal medicine know impact CYP3A4 ( eg , St. John 's wort ) within 30 day prior investigational product administration Current use medication prescribe osteoporosis treatment Use midazolam within 14 day prior investigational product administration Influenza vaccination within 28 day screen Previous exposure denosumab</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>